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Background: Autoantibody-related congenital heart block (CHB) is an autoimmune condition in which trans
placental passage of maternal autoantibodies cause damage to the developing heart conduction system of the
foetus.
Case presentation: We report a case of an Italian 31–year-old woman, in a good clinical status, referred to our
Centre at 26 weeks of her first pregnancy, because of foetal bradycardia, found during routine foetal
ultrasonography. Foetal echocardiography revealed a 3rd degree CHB, without any anatomical defects. Despite the
mother was asymptomatic for autoimmune disease, anti-Ro/La were searched for, because of the hypothesis of
autoantibody-related CHB. High title of maternal anti-Ro/SSA antibodies was found and diagnosis of an
autoantibody-related CHB was made. A combination treatment protocol of the mother was started with oral
betamethasone, plasmapheresis and IVIG. An emergency C-section was performed at 32 + 3 weeks of gestation
because of a non-reassuring cardiotocography pattern. A male newborn (BW 1515 g, NGA, Apgar 8–10) was treated
since birth with high-flow O2 for mild RDS. IVIG administration was started at one week, and then every two weeks,
until complete disappearance of maternal antibodies from blood. Because of persistent low ventricular rate
(<60/min), seven days following birth, pacemaker implantation was performed. The baby is now at 40th week with
no signs of cardiac failure and free of any medications.
Conclusion: Up to date, no guidelines have been published for the treatment of “in utero-CHB” and only anecdotal
reports are available. It has been stated that a combination therapy protocol is effective in reversing a 2nd degree
CHB, but not for 3rd degree CHB. In cases of foetal bradycardia, weekly foetal echocardiographic monitoring needs
to be performed and in cases of 2nd degree CHB and 3rd degree CHB maternal therapy could be suggested, as in
our case, to avoid foetal heart failure. In cases of 3rd degree CHB often pacemaker implantation is needed.
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Figure 1 Ultrasonograms of two-dimensional foetal echocar-
diograpy. Atrial (A) and ventricular (V) contractions.
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Autoantibody-associated congenital heart block (CHB)
is a rare neonatal disease with an overall prevalence of
1/20000 liveborn [1]. It may be detected in utero as a
1st- or 2nd-degree atrioventicular (AV) block, but most
of the affected foetuses have a potentially lethal 3rd-
degree, complete AV block [2]. Occasionally is associ-
ated a life-threatening cardiomyopathy [3].
Reported perinatal mortality rate is about 20-30% and
approximately 57-66% of children born alive with CHB
require pacemaker before reaching adulthood [4].
Autoantibody-associated CHB is considered a model
of passively acquired autoimmune disease in which the
trans-placental passage of maternal antinuclear antibodies
(ANA) causes immune-mediated inflammation of the de-
veloping myocardial tissue and conduction system of the
foetus [5].
Approximately 85% of foetus with congenital heart
block and absence of structural abnormalities have ma-
ternal transfer of antibodies against SSA/Ro and SSB/La
[6]; however only 2% of seropositive mother have new-
borns with congenital heart block [7]. This low risk rate
rises to 19% for women with a previously affected new-
born [8]. According to these data, antibodies to SSA/Ro
and SSB/La could not be the only cause of the disease and
other maternal and foetal factors are important [9]. Never-
theless, maternal health status is not considered a risk
factor for CHB; approximately 40-60% of mothers with an
affected newborn are totally asymptomatic for auto-
immune disease when foetal bradycardia is found [10].
Clinical signs of conduction abnormalities (1st, 2nd,
3rd-degree heart block) most commonly develop during
18–24 weeks of pregnancy and may be found by foetal
Doppler echocardiography [11]. CHB is considered a pro-
gressively developing disease and 3rd-degree heart block
appears to be irreversible. Nevertheless, anecdotal cases of
antenatal therapy describe the possibility of complete re-
gression of 1st and 2nd -degree heart blocks, but only a
stop of progression to heart failure for 3rd-degree heart
blocks [12,13].
Up to date, no therapy has demonstrated in large case
studies to be effective in preventing the progression of
heart injury and in reversing autoantibody-associated
CHB. We report the outcome of a combination therapy
protocol described in detail in a recent paper by Ruffatti
et al. [12] to treat a case of autoantibody-related 3rd-
degree heart blocks referred to our Neonatal Intensive
Care Unit.
Case presentation
A healthy, primigravida, asymptomatic 31-year-old woman
was referred to our Obstetric Unit at 26 weeks of gesta-
tion, because of the finding of foetal bradycardia during
routine obstetric ultrasonography examination. The foetalechocardiography, performed in our clinic, revealed dis-
sociation between atrial rhythm (154/bpm) and ventricular
rhythm (54 bpm) (Figure 1). Neither structural heart de-
fects nor hydrops fetalis were found.
Despite the mother was asymptomatic for any auto-
immune diseases, anti-Ro/La autoantibodies were searched
for, because of the possibility of autoantibodies-related
CHB. High title of maternal anti-Ro/SSA was found (359,5
U/ml) and diagnosis of an autoantibody-related CHB was
made. After prenatal counselling between neonatologists,
cardiologists, rheumatologists and obstetricians, mother
started a combination therapy protocol of plasmapheresis,
intravenous immunoglobulin and betamethasone (Figure 2).
Foetal heart rate remained stable until the 32 + 3 weeks of
gestation, when a non-reassuring cardiotocography pattern
occurred and a 1515 g male was delivered by an emergency
C- section. A male newborn (1515 g, NGA, Apgar 8–10)
was treated since birth with high-flow O2 for mild RDS.
Electrocardiography confirmed complete AV block, with
an atrial rate of 136 bpm and a ventricular rate of 44 bpm
(Figure 3), and no significant heart rate increase after iso-
proterenol (up to 0,1 μg/kg/min) administration. Newborn
serum was positive for ENA (SSA/Ro = 257U/ml) and
IVIG administration was started at one week and every
two weeks, until complete disappearance of maternal
antibodies from blood. Because of persistent low ven-
tricular rate (<60/min), seven days following birth, pace-
maker implantation was performed (Figures 3). Because
of gestational age (33w + 3) and low weight (1380 g), the
pacemaker (MICRONY TM II SR+; St.Jude Medical)
was placed in an abdominal pocket, through a left
xipho-umbilican paramedian incision, between the rec-
tus muscle sheet and the posterior surface of the ab-
dominal muscle, as already reported [14,15]. A 35 cm
bipolar steroid-eluting epicardial pacing lead was posi-
tioned on the right ventricular free wall through a left
Figure 2 The combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone. Oral betamethasone
was daily scheduled at diagnosis until the delivery date. Plasmepheresis sessions were performed daily at onset for the first 2 days, and thereafter
weekly until the delivery date. IVIG infusions was prescribed fortnightly soon after plasmapheresis. Low dose aspirin (100 mg/day) was
administered to minimize the IVIG’s thrombophilia side effects.
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The exuberant length of the cable was rolled into the
left pleural space, tunneled till the abdominal pocket
and connected to the generator. The pacemaker was
programmed with a heart rate of 120 bpm. The baby is
now 40th week with no signs of cardiac failure and free
of any medications.Figure 3 A neonatal electrocardiography shows complete atrioventric
of 44 bpm.Discussion
Autoantibody-related CHB is an autoimmune condition
in which trans-placental passage of maternal autoanti-
bodies cause damage to the developing heart conduction
system of the foetus. Up to date, no therapy is found to
be effective in the treatment of 2nd and 3rd degree
CHB. Ruffatti et al. have recently showed the possibilityular block, with an atrial rate of 136 bpm and a ventricular rate
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progression of immune-related heart damage [12,13].
The rationale behind this combined protocol is that it is
possible to obtain a sum of the effects of each drug: a)
bethametasone, a fluorinated steroids only partially inac-
tivated by the placenta, reduces inflammation of the
developing conduction system; b) plasmapheresis lowers
the level of the offending antibodies; c) IVIG made an
anti-idiotype regulation, inhibiting the placental transport
of maternal antibodies, and modulating macrophages re-
sponse with secondary reduction of inflammation and fi-
brosis of the foetal heart.
This is a report of an antibody-related complete CHB,
treated in utero with a combination therapy protocol, a
pacemaker implantation at one week of age and bi-weekly
IVIG administration to the newborn.
According to the protocol, the newborn was also
treated with IVIG after birth, and every two weeks, until
maternal autoantibodies became undetectable. The treat-
ment continued in post-natal period because, although
the pacemaker implantation preserve electrophysiological
heart failure, it does not avoid myocardial injury from per-
sistent maternal autoantibodies that may clinically mani-
fests with myocardial dysfunction after birth, even with
adequate pacemaker therapy [16]. We have also avoided
breastfeeding, because of the possible transfer human of
anti-Ro/La antibodies via breast milk and subsequent tis-
sue injury [17]. This post-natal treatment may accelerate
the clearance of potentially pathogenic autoantibodies and
avoid the risk of myocardial injury (fibrosis) progression.
No side effects related to the protocol were observed
both in the mother and newborn. Despite the case re-
ported by Ruffatti et al. [12] showed an improvement of
foetal heart rate, we were not able to demonstrate this
effect in our foetus with 3rd degree AV block, and an
early pacemaker implantation was needed after birth, at
one week of age. Probably, the timing of starting the
combined protocol during pregnancy might affect the
result in term of foetal heart rate improvement. Further
studies are needed to demonstrate the correct timing
and efficacy of this combined protocol.
Conclusion
Different therapeutic regimens have been proposed for
foetal/neonatal CHB, but controlled clinical trials are
not yet available. CHB is a progressive disease and, pre-
sumably, the best time for any therapy is during early
stages of pregnancy, when inflammation of the heart con-
duction system, but not fibrosis, is present. Thus, early as-
sessment of the foetus and serial foetal echocardiographs
to identify reversible block are needed, to start treatment
when CHB is still incomplete [18]. Multidisciplinary pre-
natal counseling is fundamental for the best treatment,
both for foetus and newborn.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor of this journal.
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